A designer natriuretic peptide (CD-NP) combining CNP with dendroaspis NP sequences showed enhanced resistance to neprilysin and other proteases while maintaining biological activity — engineered peptide drugs lasting longer.
Key findingA designer natriuretic peptide (CD-NP) combining CNP with dendroaspis NP sequences showed enhanced resistance to neprilysin and other proteases while
What the researchers found
A designer natriuretic peptide (CD-NP) combining CNP with dendroaspis NP sequences showed enhanced resistance to neprilysin and other proteases while maintaining biological activity — engineered peptide drugs lasting longer.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.
Journal of molecular and cellular cardiology, 51(1), 67-71
Citation
Dickey, Deborah M; Potter, Lincoln R. (2011). Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.. Journal of molecular and cellular cardiology, 51(1), 67-71. https://doi.org/10.1016/j.yjmcc.2011.03.013